Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen completes European registration for new bowel cleanser

Ipsen completes European registration for new bowel cleanser

11th February 2013

Sanofi has expressed satisfaction with its business performance for the 2012 full-year period, during which it generated an annual sales total of 34.95 billion euros (29.79 billion pounds).

This represented a year-on-year increase of 0.5 percent, with growth being achieved despite the loss of patent protection of several key legacy products in the US, leading to a net sales loss of 1.35 billion compared to 2011.

Sanofi was able to mitigate this impact by enhancing the performance of its diabetes portfolio and its emerging market, consumer health and vaccines divisions, while revenues from its subsidiaries Genzyme and Merial also rose.

Moreover, nine significant regulatory approvals were achieved and six new files with regulatory agencies were submitted in 2012, including positive decisions on Lyzumia and Zaltrap earlier this month, thus strengthening Sanofi's future prospects further.

Christopher Viehbacher, chief executive officer of Sanofi, said: "Despite the effect of the patent cliff, Sanofi was able to grow sales and mitigate the impact on business earnings per share … We are on track to meet our 2012-2015 objectives for sustainable growth."ADNFCR-8000103-ID-801537979-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.